Related Experiment Video
Updated: Nov 4, 2025
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Overcoming delivery barriers in immunotherapy for glioblastoma
Yuan Rui1, Jordan J Green2,3,4,5
1Department of Biomedical Engineering, the Institute for Nanobiotechnology and the Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Abstract:
Glioblastoma is one of the deadliest forms of primary adult tumors, with median survival of 14.6 months post-diagnosis despite aggressive standard of care treatment. This grim prognosis for glioblastoma patients has changed little in the past two decades, necessitating novel treatment modalities. One potential treatment modality is cancer immunotherapy, which has shown remarkable progress in slowing disease progression or even potentially curing certain solid tumors. However, the transport barriers posed by the blood-brain barrier and the immune privileged status of the central nervous system pose drug delivery obstacles that are unique to brain tumors. In this review, we provide an overview of the various physiological, immunological, and drug delivery barriers that must be overcome for effective glioblastoma treatment. We discuss chemical modification strategies to enable nanomedicines to bypass the blood-brain barrier and reach intracranial tumors. Finally, we highlight recent advances in biomaterial-based strategies for cancer immunotherapy that can be adapted to glioblastoma treatment.
Insights
Glioblastoma treatment faces significant challenges due to the blood-brain barrier and central nervous system immune privilege. Novel nanomedicine and immunotherapy strategies are being explored to overcome these obstacles for better patient outcomes.
Area of Science:
- Neuro-oncology
- Cancer immunotherapy
- Nanomedicine
Background:
- Glioblastoma is a highly aggressive primary brain tumor with a poor prognosis.
- Standard treatments offer limited survival benefits, necessitating innovative therapeutic approaches.
- Cancer immunotherapy shows promise but faces unique challenges in the central nervous system.
Purpose of the Study:
- To review the barriers to effective glioblastoma treatment.
- To discuss strategies for overcoming the blood-brain barrier and immune privilege.
- To highlight advancements in immunotherapy and nanomedicine for glioblastoma.
Main Methods:
- Literature review of physiological, immunological, and drug delivery barriers.
- Analysis of chemical modification strategies for nanomedicine delivery.
- Examination of biomaterial-based immunotherapy approaches.
Main Results:
- Identified significant physiological and immunological barriers unique to brain tumors.
- Discussed chemical modifications enabling nanomedicines to cross the blood-brain barrier.
- Highlighted potential of biomaterial-based immunotherapies for glioblastoma.
Conclusions:
- Overcoming the blood-brain barrier and CNS immune privilege is critical for glioblastoma therapy.
- Nanomedicine and immunotherapy offer promising avenues for novel glioblastoma treatments.
- Further research into advanced delivery systems and immunotherapeutic strategies is warranted.
More Related Videos
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
Related Concept Videos
01:27Tumor Immunotherapy
02:56Treatment Resistant Cancers